Stocksigma LogoStocksigma Logo

Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore

Aptus Pharma approved unaudited results for the half year ended 30th Sep'26, reporting revenue from operations of INR 48.92 crore (up 240% YoY from INR

Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore

Aptus Pharma Ltd 路 Financial Result 路 21 Oct 2026, 12:59 am

Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore Aptus Pharma approved unaudited results for the half year ended 30th Sep'26, reporting revenue from operations of INR 48.92 crore (up 240% YoY from INR 14.38 crore), EBITDA of INR 7.68 crore, and PAT surging to INR 5.08 crore versus INR 1.75 crore in the prior period. EPS stood at INR 2.96. The company approved a preferential equity issue of 16.03 lakh shares at INR 280 each, aggregating INR 44.88 crore, awaiting BSE approval. Management targets 46% geographic coverage across India by Mar'27.

Original exchange filing (PDF)

More announcements from Aptus Pharma Ltd

All Aptus Pharma Ltd announcements